Cost Management Insights: SG&A Expenses for Alkermes plc and ACADIA Pharmaceuticals Inc.

Biopharma SG&A Trends: Alkermes vs. ACADIA

__timestampACADIA Pharmaceuticals Inc.Alkermes plc
Wednesday, January 1, 201432748000199905000
Thursday, January 1, 201590804000311558000
Friday, January 1, 2016186456000374130000
Sunday, January 1, 2017255062000421578000
Monday, January 1, 2018265758000526408000
Tuesday, January 1, 2019325638000599449000
Wednesday, January 1, 2020388661000538827000
Friday, January 1, 2021396028000560977000
Saturday, January 1, 2022369090000605747000
Sunday, January 1, 2023402466000689751000
Monday, January 1, 2024645238000
Loading chart...

Unleashing the power of data

Navigating SG&A Expenses: A Tale of Two Biopharma Giants

In the competitive landscape of biopharmaceuticals, effective cost management is crucial. Over the past decade, Alkermes plc and ACADIA Pharmaceuticals Inc. have demonstrated distinct strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Alkermes consistently outpaced ACADIA, with SG&A expenses peaking at approximately 690 million in 2023, a 245% increase from 2014. In contrast, ACADIA's expenses grew by over 1,100% during the same period, reaching around 402 million in 2023. This divergence highlights Alkermes' steady growth and ACADIA's rapid expansion. Such insights are invaluable for investors and stakeholders aiming to understand the financial health and strategic priorities of these companies. As the biopharma sector evolves, monitoring these trends will be key to predicting future market dynamics.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025